Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.42 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5201629 | 0.91 | MEN1 (0.43) | MEN1KMT2AGAAGRIN2BGRIN2D | |
| SCHEMBL5204340 | 0.89 | MEN1 (0.46) | MEN1KMT2AGAAGRIN2BGRIN2D | |
| SCHEMBL5204359 | 0.76 | SLC6A4 (0.63) | GRIN2B | |
| SCHEMBL7078851 | 0.75 | MEN1 (0.52) | MEN1KMT2AGAAGRIN2BGRIN2D | |
| SCHEMBL5204351 | 0.75 | SLC6A2 (0.63) | MEN1KMT2AGRIN2BGRIN2DGRIN3B | |
| SCHEMBL7071502 | 0.73 | GRIN2B (0.60) | GRIN2B | |
| SCHEMBL6429862 | 0.71 | GAA (0.60) | GAABRCA1MAPTHTT | |
| SCHEMBL6428994 | 0.71 | GAA (0.70) | MEN1KMT2AGAAKDM4EALDH1A1 | |
| SCHEMBL5377860 | 0.71 | GRIN2D (0.52) | MEN1KMT2AGAAGRIN2BGRIN2D | |
| SCHEMBL5383885 | 0.71 | GPR84 (0.51) | MEN1KMT2AGAAGRIN2BGRIN2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304048-B2 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1178983-B1 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | SCIOS INC (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20070161649-A1 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE | SCIOS INC. | 2007-07-12 | — | — | US | disclosed |
| US-7238712-B2 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| US-7189726-B2 | Benzofuran derivatives as inhibitors of p38-α kinase | SCIOS, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-6867209-B1 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2005-03-15 | — | — | US | disclosed |
| US-6864260-B2 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-20030195355-A1 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. | 2003-10-16 | — | — | US | disclosed |
| US-20030162970-A1 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. | 2003-08-28 | — | — | US | disclosed |
| US-20030158417-A1 | Benzofuran derivatives as inhibitors of p38-alpha kinase | SCIOS, INC. | 2003-08-21 | — | — | US | disclosed |
| US-20030144520-A1 | Indole-type derivatives as inhibitors of p38 kinase | MAVUNKEL BABU J (US) | 2003-07-31 | — | — | US | disclosed |
| EP-1178983-A1 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | Scios Inc. (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000071535-A1 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE | SCIOS INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161649-A1 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE | GRK6, CSNK2A2, CSNK2A1 | MEN1 3286/4885KMT2A 2753/4885GAA 4859/4885 |
| US-20030144520-A1 | Indole-type derivatives as inhibitors of p38 kinase | CNKSR1, MAPK1, CSNK1A1 | MEN1 3998/4885KMT2A 2356/4885GAA 4792/4885 |
| US-20030158417-A1 | Benzofuran derivatives as inhibitors of p38-alpha kinase | CNKSR1, CSNK2A1, CSNK1A1 | MEN1 4593/4885KMT2A 3476/4885GAA 4397/4885 |
| US-20030162970-A1 | Indole-type derivatives as inhibitors of p38 kinase | CNKSR1, MAPK1, CSNK1A1 | MEN1 3998/4885KMT2A 2356/4885GAA 4792/4885 |
| US-20030195355-A1 | Indole-type derivatives as inhibitors of p38 kinase | CNKSR1, MAPK1, CSNK1A1 | MEN1 3998/4885KMT2A 2356/4885GAA 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.